source
- AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly dealMore details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from itsEndpoints · 4h ago↗ source
- Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stockAlnylam’s second-quarter earnings report Thursday did little to assuage investor concerns in what has already been a difficult year for the company. The drugmaker lowered its full-year sales projec…Endpoints · 6h ago↗ source
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.